Where Will AST SpaceMobile Be In 5 Years?
Ever tried to send a text from the Nevada desert…
Sell
31
MNPR Quote, Financials, Valuation and Earnings
Last price:
$34.47
Seasonality move
:
-27.37%
Day range:
$33.00 - $34.81
52-week range:
$1.72 - $54.30
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
3.82x
Volume:
42.2K
Avg. volume:
23K
1-year change:
633.24%
Market cap:
$205M
Revenue:
--
EPS (TTM):
-$4.00
Analysts' Opinion
-
Consensus RatingMonopar Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $61.27, Monopar Therapeutics has an estimated upside of 82.79% from its current price of $33.52.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $40.08 representing -19.57% downside risk from its current price of $33.52.
Fair Value
-
According to the consensus of 3 analysts, Monopar Therapeutics has 82.79% upside to fair value with a price target of $61.27 per share.
MNPR vs. S&P 500
-
Over the past 5 trading days, Monopar Therapeutics has underperformed the S&P 500 by -9.32% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Monopar Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Monopar Therapeutics has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Monopar Therapeutics reported revenues of --.
Earnings Growth
-
Monopar Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Monopar Therapeutics reported earnings per share of -$0.38.
Enterprise value:
150.4M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-14.45x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$10.6M | -$8M | -$17.7M | -$1.7M | -$3.2M | |
| EBITDA | -$10.6M | -$8M | -$17.7M | -$1.7M | -$3.2M | |
| Diluted EPS | -$4.15 | -$2.61 | -$4.00 | -$0.51 | -$0.38 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $25.8M | $18M | $11.8M | $8.9M | $55.1M | |
| Total Assets | $25.9M | $18.1M | $11.8M | $8.9M | $55.1M | |
| Current Liabilities | $806.3K | $1.1M | $2.9M | $1.4M | $1.5M | |
| Total Liabilities | $806.3K | $1.1M | $2.9M | $1.4M | $1.5M | |
| Total Equity | $25.1M | $17M | $8.9M | $7.5M | $53.6M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$7M | -$7.2M | -$10.4M | -$1.7M | -$5.7M | |
| Cash From Investing | -$5.9M | $4.9M | -$13.7M | -$983.3K | -$325.8K | |
| Cash From Financing | $854.3K | $4.4M | $56M | $3.2M | -$115.7K | |
| Free Cash Flow | -$7M | -$7.2M | -$10.4M | -$1.7M | -$5.7M | |
MNPR
Sector
Market Cap
$205M
$32.3M
Price % of 52-Week High
61.73%
46.89%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.66%
1-Year Price Total Return
633.24%
-37.62%
Beta (5-Year)
0.991
0.632
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$35.23
200-day SMA
Buy
Level
$26.20
Bollinger Bands (100)
Sell
Level
32.07 - 43.25
Chaikin Money Flow
Sell
Level
-26.3M
20-day SMA
Sell
Level
$34.66
Relative Strength Index (RSI14)
Sell
Level
44.51
ADX Line
Sell
Level
9.91
Williams %R
Neutral
Level
-53.5811
50-day SMA
Sell
Level
$36.88
MACD (12, 26)
Sell
Level
-0.88
25-day Aroon Oscillator
Sell
Level
-56
On Balance Volume
Neutral
Level
147.5M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
Stock Forecast FAQ
In the current month, MNPR has received 2 Buy ratings 1 Hold ratings, and 0 Sell ratings. The MNPR average analyst price target in the past 3 months is $61.27.
-
Where Will Monopar Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Monopar Therapeutics share price will rise to $61.27 per share over the next 12 months.
-
What Do Analysts Say About Monopar Therapeutics?
Analysts are divided on their view about Monopar Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Monopar Therapeutics is a Sell and believe this share price will drop from its current level to $40.08.
-
What Is Monopar Therapeutics's Price Target?
The price target for Monopar Therapeutics over the next 1-year time period is forecast to be $61.27 according to 3 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is MNPR A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Monopar Therapeutics is a Buy. 2 of 3 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of MNPR?
You can purchase shares of Monopar Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Monopar Therapeutics shares.
-
What Is The Monopar Therapeutics Share Price Today?
Monopar Therapeutics was last trading at $34.47 per share. This represents the most recent stock quote for Monopar Therapeutics. Yesterday, Monopar Therapeutics closed at $33.52 per share.
-
How To Buy Monopar Therapeutics Stock Online?
In order to purchase Monopar Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is TTD The Big Winner If Pharma Ads Are Banned?
Last week, Senators Bernie Sanders and Angus King introduced a…
Is Palantir Stock Overvalued?
By every traditional yardstick, including a price‑to‑sales well above 100,…
Stock Ideas
Buy
65
Is MSFT Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 40x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 48x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 32x
Alerts
Sell
11
VEON alert for Jun 16
VEON [VEON] is up 2.47% over the past day.
Buy
74
DAVE alert for Jun 16
Dave [DAVE] is up 3.1% over the past day.
Buy
54
DAR alert for Jun 16
Darling Ingredients [DAR] is up 7.41% over the past day.
